Unknown

Dataset Information

0

Optimized Antimicrobial Peptide Jelleine-I Derivative Br-J-I Inhibits Fusobacterium Nucleatum to Suppress Colorectal Cancer Progression.


ABSTRACT: Colorectal cancer (CRC) is a major health burden worldwide due to its high morbidity, mortality, and complex etiology. Fusobacterium nucleatum (Fn), a Gram-negative anaerobe found in 30% of CRC patients, promotes CRC carcinogenesis, metastasis, and chemoresistance. Effective antimicrobial treatment is an unmet need for the rising CRC burden. Antimicrobial peptides (AMPs) represent a new class of antimicrobial drugs. In our previous study, we did the structure-activity study of Jelleine-I (J-I) and identified several halogenated J-I derivatives Cl-J-I, Br-J-I, and I-J-I. To determine whether those J-I derivatives can be a new therapy for bacterial-associated CRC, here we tested the antibacterial activities of these AMPs against Fn and their effects on CRC development. We found that Br-J-I showed the highest anti-Fn activity and Br-J-I may target membrane-associated FadA for Fn membrane disruption. More importantly, Fn promoted the growth of CRC cells-derived xenograft tumors. Br-J-I suppressed Fn load, colon inflammation, and Fn-induced CRC growth. Of note, Br-J-I induced better anti-CRC effects than common antibiotic metronidazole and Br-J-I sensitized the cancer-killing effect of chemotherapy drug 5-fluorouracil. These results suggest that Br-J-I could be considered as an adjunctive agent for CRC treatment and AMPs-based combination treatment is a new strategy for CRC in the future.

SUBMITTER: Jia F 

PROVIDER: S-EPMC9865857 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Optimized Antimicrobial Peptide Jelleine-I Derivative Br-J-I Inhibits Fusobacterium Nucleatum to Suppress Colorectal Cancer Progression.

Jia Fengjing F   Yu Qun Q   Wang Ruolei R   Zhao Ling L   Yuan Fuwen F   Guo Haidong H   Guo Haidong H   Shen Yunhui Y   He Feng F  

International journal of molecular sciences 20230111 2


Colorectal cancer (CRC) is a major health burden worldwide due to its high morbidity, mortality, and complex etiology. <i>Fusobacterium nucleatum</i> (<i>Fn</i>), a Gram-negative anaerobe found in 30% of CRC patients, promotes CRC carcinogenesis, metastasis, and chemoresistance. Effective antimicrobial treatment is an unmet need for the rising CRC burden. Antimicrobial peptides (AMPs) represent a new class of antimicrobial drugs. In our previous study, we did the structure-activity study of Jell  ...[more]

Similar Datasets

| S-EPMC6607099 | biostudies-literature
| S-EPMC4537376 | biostudies-literature
| S-EPMC9775898 | biostudies-literature
| S-EPMC4769120 | biostudies-literature
| S-EPMC6618585 | biostudies-literature
| S-EPMC3266037 | biostudies-literature
| S-EPMC11006615 | biostudies-literature
| S-EPMC10492297 | biostudies-literature
| S-EPMC5767127 | biostudies-literature
| S-EPMC5543402 | biostudies-literature